稳定型冠心病他汀治疗患者PCSK9抑制的个体终生获益估计
本研究基于TNT试验阿托伐他汀80mg组4853例稳定型冠心病患者数据,构建竞争风险模型并叠加PCSK9抑制的相对效应,估计个体终生免于卒中或心肌梗死的获益月数。结果显示61%患者获益<6个月,28%为6-12个月,10%≥12个月,中位5个月;年轻且危险因素负担重、LDL-C>1.8 mmol/L者获益最大。
要点
- 稳定型冠心病他汀治疗患者中,PCSK9抑制的个体终生获益差异大,中位仅5个月。
- 年轻(40-60岁)、危险因素多且LDL-C>1.8 mmol/L者获益最高。
- ≥70岁且LDL-C及危险因素水平低者获益最低(≤5个月)。
核心结论
- 稳定型冠心病高剂量他汀治疗患者接受PCSK9抑制的个体终生免于卒中或心肌梗死获益从<6个月到≥12个月不等。
- 获益最高预期见于年轻(40-60岁)、危险因素负担重且LDL-C相对较高的患者。
研究设计与样本
- 基于TNT试验阿托伐他汀80mg组4853例稳定型冠心病患者数据开发两个竞争风险模型。
- 将PCSK9抑制的相对效应叠加于模型,假设LDL-C降低50%且每降低1 mmol/L(39 mg/dL)心血管风险降低21%。
主要发现
- 估计个体获益<6个月者占61%,6-12个月者占28%,≥12个月者占10%(中位5个月,四分位2-8个月)。
- 获益最高见于年轻(40-60岁)且危险因素负担重、尤其LDL-C>1.8 mmol/L(>70 mg/dL)的患者。
- 获益最低(≤5个月)见于老年(≥70岁)患者,尤其LDL-C及其他危险因素水平低者。
关键数值与推荐
- 个体终生获益以至80岁免于卒中或心肌梗死的月数计。
- PCSK9抑制假设LDL-C降低50%,每降低1 mmol/L(39 mg/dL)LDL-C心血管风险降低21%。
临床怎么用
- 可依据年龄、危险因素负担和LDL-C水平个体化评估稳定型冠心病患者PCSK9抑制的终生获益。
- 年轻、危险因素多且LDL-C>1.8 mmol/L的患者可能从PCSK9抑制中获益更大。
局限性
- PCSK9抑制的相对效应基于大型临床试验的平均估计而非本研究直接观察。
- 预测模型源于TNT试验阿托伐他汀80mg组人群,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In statin-treated patients with stable coronary artery disease (CAD), residual risk of cardiovascular events is partly explained by plasma levels of low-density lipoprotein cholesterol (LDL-C). This study aimed to estimate individual benefit of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition in CAD patients already treated with high-dose statin. METHODS: Individual lifetime benefit was estimated in months gain free of stroke or myocardial infarction (MI) until age 80 years. Predictions were based on two competing risk models developed in data from 4853 patients with CAD originating from the atorvastatin 80 mg arm of the Treating to New Targets (TNT) trial. The relative effect of PCSK9 inhibition was added to the models and was assumed based on average estimates from large clinical trials. We accounted for individual LDL-C levels, assuming 50% LDL-C reduction by PCSK9 inhibition and 21% cardiovascular risk reduction per mmol/L (39 mg/dL) LDL-C lowering. RESULTS: Estimated individual gain was <6 months in 61% of the patients, 6-12 months in 28% of the patients and ≥12 months in 10% of the patients (median 5, quartiles 2-8 months). Highest estimated benefit was observed in younger patients (aged 40-60 years) with high risk factor burden, particularly if LDL-C levels were >1.8 mmol/L (>70 mg/dL). Estimated benefit was lowest (≤5 months) in older patients (≥70 years), in particular if LDL-C and other risk factors levels were low. CONCLUSION: The individual estimated lifetime benefit from PCSK9 inhibition in patients with stable CAD on high-dose statin varied from <6 to ≥12 months free of stroke or MI. Highest benefit is expected in younger patients (age 40-60 years) with high risk factor burden and relatively high LDL-C levels. TRIAL REGISTRATION NUMBER: NCT00327691; Post-results.
引用
- Kaasenbrood L, Ray KK, Boekholdt SM, et al. Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. Heart. 2018. PMID: 29622600. doi:10.1136/heartjnl-2017-312510
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。